Connect with us

Hi, what are you looking for?

Health Care Sector

Colombia approves use of Cuba’s Cancer Drug CIMAher

Photo: BioCubaFarma

BioCubaFarma reported in its Twitter account that Colombia’s Ministry of Health and Protection has approved Cuba’s cancer drug CIMAher. The drug will be available under Colombia’s Health Benefits Plan.

BioCubaFarm said the decision will allow doctors in Colombia to prescribe the drug.

Scientists at the Center for Molecular Immunology (CIM) developed the cancer drug.

CIMAher is a humanized antibody used in patients with inoperable esophageal cancer of epithelial origin in combination with chemotherapy, and as a combined treatment for advanced-stage squamous cell cancer of the head and neck.

It is also used to extend the life of children with highly malignant astrocytoma, resistant to other treatments.

A study carried out in patients with esophageal cancer, when treated with CIMAher, alongside chemotherapy, demonstrated positive response and survival rates.

According to the Cuban Health Network (Infomed), patients in the study in an advanced stage of the disease, the control rate was 83%, with the objective response rate of 64.9%.

Information source: CubaDebate

Advertisement. Scroll to continue reading.
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Related News:

Health Care Sector

Russia and Cuba to begin research on new cancer drug. On Wednesday the representative of BioCubaFarma in Russia and the national company Alphanil signed...

Health Care Sector

Opening day ceremonies for the new China-Cuba Biotech Center took place in Yongzhou, Hunan province. Carlos Miguel Pereira, the Cuban Ambassador to China, and...

Health Care Sector

Cuba and Argentina will collaborate in health and biotechnology. The nations’ Health Ministers, Doctors José Ángel Portal and Carla Vizzotti, signed a letter of...

Health Care Sector

The BioCubaFarma business group is in the process of penetrating the Russian market with its innovative pharmaceutical products. The year 2021 will be a...

error: This content is copyright protected.